FrancophonIA/ELRC3.0 huggingface dataset:
English: Side effects reported with Ervebo are carefully evaluated and any necessary action taken to protect patients.
Estonian: Ervebo kõrvalnähte hinnatakse hoolikalt ja patsientide kaitseks võetakse vajalikke meetmeid.
English: Later, when the person comes into contact with the actual virus, the immune system recognises the virus protein and is already prepared to attack the virus and so protects the person from Ebola virus disease.
Estonian: Hiljem, kui inimene puutub kokku tegeliku viirusega, tunneb tema immuunsüsteem viirusvalgu ära ja on juba valmis viirust ründama, kaitstes teda nii Ebola viirushaiguse eest.
English: Healthcare workers and other carers who have been vaccinated with Ervebo should also continue to apply standard precautions for safe injection and hygiene and wear personal protective equipment when caring for patients with known or suspected Ebola virus disease.
Estonian: Tervishoiutöötajad ja hooldajad, keda on vaktsineeritud Erveboga, peaksid samuti jätkuvalt rakendama standardseid ohutu süstimise ja hügieeni ettevaatusabinõusid ning kandma teadaoleva või oletatava Ebola viirushaigusega patsientide hooldamisel isikukaitsevahendeid.
English: In general, these reactions occur within 7 days after vaccination, were mild to moderate in intensity and resolved in less than a week.
Estonian: Enamasti ilmnesid need kerged kuni mõõdukad reaktsioonid 7 päeva jooksul pärast vaktsineerimist ja kadusid vähem kui nädalaga.
English: Ervebo is given by a trained healthcare worker.
Estonian: Ervebot tohib manustada üksnes erikoolitusega tervishoiutöötaja.
English: A main study showed that Ervebo was effective in preventing Ebola virus disease in adults at risk of infection during an outbreak.
Estonian: Põhiuuring tõendas Ervebo efektiivsust Ebola viirushaiguse ennetamisel nakatumise riskiga täiskasvanutel haiguspuhangu ajal.
English: The effectiveness of the vaccine to protect against confirmed Ebola virus disease was measured by comparing the number of cases occurring 10 to 31 days after vaccination in the group of people vaccinated immediately, versus the number of cases in the group of people who were vaccinated later.
Estonian: Vaktsiini efektiivsust kinnitatud Ebola viirushaiguse vastu kaitsmisel mõõdeti, võrreldes 10-31 päeva pärast vaktsineerimist esinenud haigusjuhtude arvu kohe ja hiljem vaktsineeritute seas.
English: The study was conducted in Guinea during an Ebola outbreak and involved people who were either direct contacts or contacts of contacts of someone who had Ebola virus disease.
Estonian: Uuring tehti Guineas Ebola viiruse puhangu ajal ja selles osalesid inimesed, kellele oli otsene või kaudne kokkupuude Ebola viirushaigusesse nakatunuga.
English: People vaccinated with Ervebo should continue to take precautions to protect themselves from Ebola virus disease.
Estonian: Erveboga vaktsineeritud isikud peaksid jätkuvalt rakendama ettevaatusabinõusid, et kaitsta end Ebola viirushaiguse eest.
English: Side effects with Ervebo were similar to those of most vaccines; they were mild to moderate in intensity and generally lasted less than a week.
Estonian: Ervebo kerged kuni mõõdukad kõrvalnähud sarnanesid enamiku vaktsiinide kõrvalnähtudega ja kestsid üldiselt alla nädala.
English: Ervebo is a vaccine to protect adults aged 18 years and older against Ebola virus disease caused by the Zaire Ebola virus.
Estonian: Ervebo on vaktsiin, millega kaitstakse vähemalt 18-aastaseid täiskasvanuid Zaire'i Ebola viiruse põhjustatud Ebola viirushaiguse eest.
English: How is Ervebo used?
Estonian: Kuidas Ervebot kasutatakse?
English: An overview of Ervebo and why it is authorised in the EU
Estonian: Ülevaade vaktsiinist Ervebo ja ELis müügiloa väljastamise põhjendus
English: Ervebo contains a virus known as vesicular stomatitis virus which has been weakened and modified to contain a protein from the Zaire Ebola virus.
Estonian: Ervebo sisaldab vesikulaarse stomatiidi viirust, mida on nõrgestatud ja modifitseeritud, et see sisaldaks Zaire'i Ebola viiruse valku.
English: How does Ervebo work?
Estonian: Kuidas Ervebo toimib?
English: Ervebo has been given ‘conditional authorisation'.
Estonian: Ervebo on saanud müügiloa tingimusliku heakskiidu alusel.
English: Ervebo should be used in individuals at risk of infection with Ebola virus.
Estonian: Ervebot kasutatakse inimestel, kellel on Ebola viirusega nakatumise risk.
English: The active substance in Ervebo contains a protein found on the Ebola Zaire virus.
Estonian: Ervebo toimeaine sisaldab Zaire'i Ebola viiruse pinnavalku.
English: For the full list of side effects and restrictions of Ervebo, see the package leaflet.
Estonian: Ervebo kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: When a person receives the vaccine, it triggers an immune response against the virus protein.
Estonian: Pärast vaktsineerimist tekib immuunvastus viirusvalgu vastu.
English: What benefits of Ervebo have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Ervebo kasulikkus?
English: These usually disappear within one to two days without treatment.
Estonian: Need kaovad tavaliselt ühe-kahe päeva jooksul ilma ravita.
English: This helps to protect against the disease.
Estonian: See aitab haiguse vastu kaitsta.
English: 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 84 16 E-mail: mail@emea.europa.eu http://www.emea.europa.eu©EMEA 2007 Reproduction and/or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged
Estonian: 7 Westferry Circus, Canary Wharf,LondonE14 4HB, UK Tel. (44-20) 74 18 84 00Fax (44-20) 74 18 84 16 E-mail: mail@emea.europa.eu http://www.emea.europa.eu©EMEA 2007 Reproduction and/or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged
English: It contains a flu strain called A/Viet Nam/1194/2004 (H5N1).
Estonian: See sisaldab gripiviiruse tüve A/Viet Nam/1194/2004 (H5N1).
English: The European Commission granted a marketing authorisation valid throughout the EU for Daronrix to GlaxoSmithKline Biologicals s.a. on 21 March 2007.
Estonian: Euroopa Komisjon väljastas Daronrixi müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, ettevõttele GlaxoSmithKline Biologicals s.a. 21. märtsil 2007.
English: It is given by injection into the upper arm muscle.
Estonian: Seda süstitakse käsivarre ülaosa lihasesse.
English: They can test this vaccine to see how people react to it, allowing them to predict how people will react when the flu strain causing a pandemic is included.
Estonian: Nad võivad seda vaktsiini testida, et näha, kuidas inimesed sellele reageerivad, mis võimaldab neil prognoosida, kuidas inimesed reageerivad, kui see sisaldab pandeemiat põhjustavat gripitüve.
English: Every year, the European Medicines Agency (EMEA) will review any new information that may become available and this summary will be updated as necessary.
Estonian: Euroopa Ravimiamet vaatab kõik võimalikud uued andmed iga aasta uuesti läbi ning vajadusel uuendab käesolevat kokkuvõtet.
English: This will include information on its side effects and its safety in children, pregnant women, patients with severe conditions, and people who have problems with their immune systems.
Estonian: See hõlmab teavet selle kõrvaltoimete kohta ja selle ohutuse kohta lastel, rasedatel, raskesti haigetel patsientidel ja immuunsüsteemi häiretega inimestel.
English: 21 days after the second injection, 70.8% of the people receiving the vaccine had levels of antibodies that would protect them against H5N1.
Estonian: 21 päeva pärast teist süsti oli 70,8%-l vaktsiini saanud inimestest selline antikehade tase, mis kaitseks neid H5N1 vastu.
English: Vaccines work by ‘teaching' the immune system (the body's natural defences) how to defend itself against a disease.
Estonian: Vaktsiinid toimivad „õpetades” immuunsüsteemi (keha loomulikke kaitsemehhanisme) ennast haiguse eest kaitsma.
English: The virus is whole, but it has been inactivated (killed) so that it does not cause disease.
Estonian: Viirus on terviklik, kuid inaktiveeritud (surmatud) ning seega haigust ei põhjusta.
English: The main measures of effectiveness were the levels of antibodies against the flu virus in the patients' blood before vaccination, on the day of the second injection (day 21), and 21 days later (day 42).
Estonian: Efektiivsust mõõdeti põhiliselt gripiviirusevastaste antikehade taseme järgi patsiendi veres enne vaktsineerimist, teise süsti päeval (21. päev) ja 21 päeva hiljem (42. päev).
English: This means that because the strain of flu virus that may cause a pandemic is not known, it has not been possible to obtain full information about the future pandemic vaccine.
Estonian: See tähendab, et kuna pandeemiat põhjustav gripiviiruse tüvi ei ole teada, polnud võimalik hankida tulevase pandeemiavaktsiini kohta täielikku teavet.
English: Before a pandemic starts, nobody knows which strain of flu virus will be involved, so companies cannot prepare the correct vaccine in advance.
Estonian: Enne pandeemia algust ei tea keegi, milline gripiviiruse tüvi selles osaleb, mistõttu ettevõtted ei saa õiget vaktsiini varem ette valmistada.
English: If a pandemic has started, however, it may be appropriate to give the vaccine to these patients, as long as facilities for resuscitation are available.
Estonian: Kui aga pandeemia on alanud, võib osutuda vajalikuks manustada vaktsiini ka neile patsientidele, kui elustamisvahendid on käepärast.
English: Daronrix would be given according to official recommendations.
Estonian: Daronrixi antakse ametlike soovituste kohaselt.
English: This is a special type of vaccine that can be developed to help with the management of a pandemic.
Estonian: See on vaktsiini eriliik, mis võidakse välja töötada pandeemia ohjeldamiseks.
English: This summary was last updated in 03-2007.©EMEA 2007
Estonian: Kokkuvõtte viimane uuendus: 03-2007.
English: EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) DARONRIX EPAR summary for the public
Estonian: EUROOPA AVALIK HINDAMISARUANNE DARONRIX Kokkuvõte üldsusele
English: Instead, they can prepare a vaccine that contains a strain of flu virus specifically chosen because nobody has been exposed to it, and to which nobody is immune.
Estonian: Selle asemel võivad nad ette valmistada vaktsiini, mis sisaldab spetsiaalselt valitud gripiviiruse tüve, kuna mitte keegi ei ole sellega kokku puutunud ja mitte keegi ei ole selle suhtes immuunne.
English: Which measures are being taken to ensure the safe use of Daronrix?
Estonian: Milliseid meetmeid võetakse, et tagada Daronrixi kasutamise ohutus?
English: Daronrix should not be given to patients who have had an anaphylactic reaction (severe allergic reaction) to any of the components of the vaccine, or to any substances found at trace levels in the vaccine, such as eggs, chicken protein or gentamicin sulphate (an antibiotic).
Estonian: Daronrixi ei tohi manustada patsientidele, kellel on tekkinud anafülaktiline reaktsioon (raske allergiline reaktsioon) vaktsiini mõne komponendi või mõne aine suhtes, mida vaktsiin mikrokogustes sisaldab, näiteks munad, kanavalk või gentamitsiinsulfaat (antibiootikum).
English: Daronrix contains small amounts of a virus called H5N1.
Estonian: Daronrix sisaldab väheses koguses viirust H5N1.
English: Daronrix is given in two doses, at least three weeks apart.
Estonian: Daronrixi manustatakse kahe annusena, mille vahele peab jääma vähemalt kolm nädalat.
English: The study showed that Daronrix containing 15 micrograms of haemagglutinin and the adjuvant produced an antibody response that satisfies these criteria.
Estonian: Uuring näitas, et Daronrix, mis sisaldab 15 mikrogrammi hemaglutiniini ja adjuvanti, kutsus esile antikehade reaktsiooni, mis vastab neile kriteeriumidele.
English: Daronrix is a vaccine that can only be used once a flu ‘pandemic' has been officially declared by the World Health Organization (WHO) or European Union (EU).
Estonian: Daronrix on vaktsiin, mida võib kasutada ainult Maailma Tervishoiuorganisatsiooni või ELi poolt ametlikult välja kuulutatud pandeemia korral.
English: According to criteria laid down by the Committee for Medicinal Products for Human Use (CHMP), a mock-up vaccine needs to bring about protective levels of antibodies in at least 70% of people for it to be considered suitable.
Estonian: Inimtervishoius kasutatavate ravimite komitee kriteeriumide kohaselt võib vaktsiini mudelit sobivaks pidada, kui see kutsub esile antikehade kaitsva taseme vähemalt 70%-l inimestest.
English: They will then collect information on the safety and effectiveness of the final pandemic vaccine, and submit this to the CHMP for evaluation.
Estonian: Samal ajal kogub ettevõte andmeid lõpliku pandeemiavaktsiini ohutuse ja efektiivsuse kohta ning esitab need inimtervishoius kasutatavate ravimite komiteele hindamiseks.
English: The vaccine also contains an ‘adjuvant' (a compound containing aluminium) to stimulate a better response.
Estonian: Vaktsiin sisaldab parema ravivastuse stimuleerimiseks ka adjuvanti (alumiiniumiühendit).
English: When a person is given the vaccine, the immune system recognises the inactivated virus as ‘foreign' and makes antibodies against it.
Estonian: Kui vaktsiini inimesele manustatakse, peab immuunsüsteem nõrgestatud viirust „võõraks” ning produtseerib selle vastu antikehi.
English: If Daronrix is used during a pandemic, the company that makes it will collect information on the safety of the vaccine while it is being used.
Estonian: Kui Daronrixi kasutatakse pandeemia ajal, kogub seda tootev ettevõte vaktsiini kasutamise ajal teavet selle ohutuse kohta.
English: What information is still awaited for Daronrix?
Estonian: Millist teavet Daronrixi kohta veel oodatakse?
English: A flu pandemic occurs when a new type (strain) of flu virus emerges that can spread easily from person to person because people have no immunity (protection) against it. A pandemic can affect most countries and regions around the world.
Estonian: Gripipandeemia tekib, kui ilmub uus gripiviiruse tüüp (tüvi), mis võib kergesti levida inimeselt inimesele, kuna inimestel puudub selle vastu immuunsus (kaitse).
English: The immune system will then be able to produce antibodies more quickly when it is exposed to the virus again.
Estonian: Kui immuunsüsteem seejärel viirusega uuesti kokku puutub, on see võimeline tootma antikehi kiiremini.
English: The committee recommended that Daronrix be given marketing authorisation.
Estonian: Daronrixile soovitati anda müügiluba.
English: The most common side effects with Daronrix (seen in more than 1 in 10 people) are headache, pain and redness at the site of the injection, and fatigue (tiredness).
Estonian: Daronrixi kõige sagedasemad kõrvaltoimed (täheldatud rohkem kui ühel inimesel kümnest) on peavalu, valu ja punetus süstekohal ning väsimus.
English: The CHMP concluded that Daronrix's benefits outweighed its risks, and that it had shown its suitability as a mock-up vaccine in preparation for a pandemic flu outbreak.
Estonian: Inimtervishoius kasutatavate ravimite komitee jõudis otsusele, et Daronrixi kasulikkus on suurem kui sellega kaasnevad riskid ning et see on osutunud sobivaks vaktsiini mudeliks valmistumaks gripipandeemiaks.
English: The main study of Daronrix included 387 healthy adults and compared the ability of different doses of Daronrix, with or without the adjuvant, to trigger the production of antibodies (immunogenicity).
Estonian: Peamises uuringus Daronrixi kasutamise kohta osales 387 tervet täiskasvanut ja selles võrreldi Daronrixi erinevate annuste võimet kasutamisel koos adjuvandiga esile kutsuda antikehade tekkimist (immunogeensust).
English: If a pandemic is declared, and if the company that makes Daronrix decides to market the vaccine, they will include the flu strain responsible in the vaccine.
Estonian: Kui pandeemia on välja kuulutatud ja kui Daronrixi tootev ettevõte otsustab vaktsiini müügile lasta, lisab ta vaktsiinisse seda põhjustanud gripitüve.
English: It is a suspension for injection that contains influenza (flu) viruses that have been inactivated (killed).
Estonian: Seda turustatakse süstesuspensioonina, mis sisaldab inaktiveeritud (surmatud) gripiviirusi.
English: Why has Daronrix been approved?
Estonian: Miks Daronrix heaks kiideti?
English: What is Daronrix?
Estonian: Mis on Daronrix?
English: If a pandemic starts, the virus strain in Daronrix will be replaced by the strain causing the pandemic before the vaccine can be used.
Estonian: Kui algab pandeemia, asendatakse enne vaktsiini kasutamist Daronrixis sisalduv viirusetüvi pandeemiat põhjustanud tüvega.
English: Other information about Daronrix:
Estonian: Muu teave Daronrixi kohta
English: Daronrix is a vaccine.
Estonian: Daronrix on vaktsiin.
English: The participants received two injections of Daronrix, containing one of four different amounts of haemagglutinin (a protein found in flu viruses), with or without the adjuvant, 21 days apart.
Estonian: Osalejad said 21-päevase intervalliga kaks Daronrixi süsti, mis sisaldasid üht neljast erinevast hemaglutiinikogusest (gripiviirustes leiduv valk) koos adjuvandiga või ilma.
English: For the full list of all side effects reported with Daronrix, see the Package Leaflet.
Estonian: Daronrixi kohta teatatud kõrvalnähtude täieliku loetelu leiate pakendi infolehelt.
English: What is the risk associated with Daronrix?
Estonian: Millised on Daronrixiga kaasnevad riskid?
English: The effects of Daronrix were first tested in experimental models before being studied in humans.
Estonian: Enne inimuuringuid kontrolliti Daronrixi toimet muude katsetega.
English: Daronrix is a ‘mock-up' vaccine.
Estonian: Daronrix on vaktsiini mudel.
English: The full EPAR for Daronrix can be found here.
Estonian: Daronrixi Euroopa avaliku hindamisaruande täisteksti leiate siit.
English: How does Daronrix work?
Estonian: Kuidas Daronrix toimib?
English: How is Daronrix used?
Estonian: Kuidas Daronrixi kasutatakse?
English: What benefit has Daronrix shown during the studies?
Estonian: Milles seisneb uuringute põhjal Daronrixi kasulikkus?
English: What is Daronrix used for?
Estonian: Milleks Daronrixi kasutatakse?
English: Daronrix has been authorised under “Exceptional Circumstances”.
Estonian: Daronrixile anti müügiluba erandkorras.
English: How has Daronrix been studied?
Estonian: Kuidas Daronrixi uuriti?
English: Conditions or restrictions with regard to the safe and effective use of the medicinal product to be implemented by the Member States
Estonian: Ravimpreparaadi ohutu ja efektiivse kasutamise tingimused ja piirangud liikmesriikides rakendamiseks
English: NovoSeven has been approved in the European Union since 1996.
Estonian: NovoSeven on Euroopa Liidus olnud heaks kiidetud alates 1996. aastast.
English: What is NovoSeven?
Estonian: Mis on NovoSeven?
English: The Company submitted the results of three studies, involving a total of 486 patients.
Estonian: Ettevõte esitas 486 patsienti hõlmanud kolme uuringu tulemused.
English: The application was at Day 157 when the Company withdrew it.
Estonian: Taotluse läbivaatamine oli kestnud 157 päeva, kui ettevõte selle tagasi võttis.
English: Following CHMP opinion, it usually takes around 6 weeks to the European Commission to update the licence.
Estonian: Inimtervishoius kasutatavate ravimite komitee arvamuse järel kulub tavaliselt ligikaudu 6 nädalat, enne kui Euroopa Komisjon loa uuendab.
English: International Non-proprietary Name (INN): eptacog alfa (activated)
Estonian: Rahvusvaheline mittekaubanduslik nimetus (INN): eptakog-alfa (aktiveeritud)
English: The letter from the Company notifying the EMEA of the withdrawal of the application is available here.
Estonian: Ettevõtte poolt Euroopa Ravimiametile saadetud kiri, milles teatatakse taotluse tagasivõtmisest, on avaldatud siin.
English: The main study was carried out in 399 patients (aged 66 on average), and compared the effectiveness of three dosages of NovoSeven to that of a placebo (dummy treatment).
Estonian: Põhiuuringus osales 399 patsienti (keskmiselt 66-aastased), selles võrreldi NovoSeveni kolme annuse tõhusust platseeboga (näiv ravim).
English: There are no consequences for NovoSeven's use in the indications for which it is already authorised, where the known benefit and risk remain unchanged.
Estonian: Tagasivõtmine ei mõjuta NovoSeveni kasutamist näidustuste korral, mille suhtes on müügiluba juba antud ning mille puhul teadaolev kasulikkus ja ohud ei ole muutunud.
English: QUESTIONS AND ANSWERS ON WITHDRAWAL OF THE APPLICATION FOR A CHANGE TO THE MARKETING AUTHORISATION for NOVOSEVEN
Estonian: TEAVE MÜÜGILOA MUUTMISE TAOTLUSE TAGASIVÕTMISE KOHTA
English: On 3 April 2006, Novo Nordisk A/S has officially notified the Committee for Medicinal Products for Human Use (CHMP) that they wish to withdraw their application for a new indication for NovoSeven, in the treatment of acute intracerebral haemorrhage (ICH) in adults for limiting haemorrhage growth and improving clinical outcome.
Estonian: 2006. aasta 3. aprillil teavitas ettevõte Novo Nordisk A/S ametlikult inimtervishoius kasutatavate ravimite komiteed oma soovist tagasi võtta taotlus ravimi NovoSeven kasutamiseks uue näidustuse, hemorraagia arenemise pidurdamiseks ja kliinilise tulemuse parandamiseks akuutset intratserebraalset hemorraagiat põdevatel täiskasvanutel.
English: What are the consequences of the withdrawal for patients undergoing clinical trials / compassionate use programmes with NovSeven?
Estonian: Millised on taotluse tagasivõtmise tagajärjed praegu NovoSeveni kliinilistes uuringutes või eriloaga kasutamise programmides osalevatele patsientidele?
English: It increases the production of thrombin, another coagulation factor, on the surface of the particles that make up blood clots (the platelets), and this helps producing a stable ‘plug' at the site of bleeding.
Estonian: Ta soodustab trombiini (muu hüübimistegur) tekkimist vereliistakute pinnal (osakesed, mis moodustavad verehüübeid), ja see aitab moodustada veritsuskohal stabiilse „korgi“.
English: What documentation has been presented by the Company to support the application to the CHMP?
Estonian: Millised dokumendid esitas ettevõte inimtervishoius kasutatavate ravimite komiteele oma taotluse toetuseks?
English: The data submitted show that NovoSeven has an effect on the volume of the haemorrhage, but it is not clear how this effect translates into a better outcome for the patient, especially at the dose selected for this indication.
Estonian: Esitatud andmetest ilmneb, et NovoSeven mõjutab hemorraagia mahtu, kuid ei selgu, kas sama toime ja eelkõige näidustuse järgi valitud annus parandab patsiendi seisundit.
English: In addition, there were concerns on the thromboembolic side effects (excessive clotting) for this indication, but the number of patients treated was too small for the CHMP to be able to balance this risk against the potential benefit.
Estonian: Lisaks sellele tekitasid ettevaatlikkust näidustusega kaasnevad trombemboolia kõrvalnähud (hüüvete liigne teke), kuid ravitud patsientide arv oli ohu ja võimaliku kasu vahekorra kohta otsuse langetamiseks liiga väike.
English: The Company has informed the CHMP that the current clinical trial of NovoSeven in intracerebral haemorrhage will continue.
Estonian: Ettevõte on teatanud inimtervishoius kasutatavate ravimite komiteele, et praegused kliinilised uuringud NovoSeveni kasutamise kohta intratserebraalse hemorraagia raviks jätkuvad.
English: Based on the review of the data and the company's response to the CHMP list of questions, at the time of the withdrawal, the CHMP had concerns and was of the provisional opinion that NovoSeven could not be approved for the treatment of acute intracerebral haemorrhage.
Estonian: Tuginedes esitatud andmete analüüsile ja ettevõtte vastustele inimtervishoius kasutatavate ravimite komitee poolt esitatud küsimustele, nägi inimtervishoius kasutatavate ravimite komitee taotluse tagasivõtmise ajal põhjust ettevaatlikkuseks ning oli esialgsel seisukohal, et NovoSeveni kasutamist intratserebraalse hemorraagiaga patsientide raviks ei ole võimalik heaks kiita.